Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell linesKeisuke Taniguchi(Yakult Honsha (Japan)), Akira Asai(University of Shizuoka)Research SquareDecember 23, 202010.21203/rs.3.rs-123999/v1Cited by 1SaveCiteExport RISWatch citationsRelated PapersEfficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines|Scientific Reports|2021|12